[转移贴]Nat Med: 一种肾癌疫苗比化疗效果更好
原帖由论坛503814发表于 2012-8-1 14:50 |新一期英国《自然—医学》杂志刊登报告说，德国研究人员对一种肾癌疫苗进行了人体临床试验，结果显示它安全有效，与化学疗法相比效果更好，并且副作用更少。
德国蒂宾根大学等机构的研究人员报告说，这种代号为IMA901的疫苗可以促使人体自身免疫系统抵抗癌症。研究人员对96名肾癌患者展开了临床试验，结果显示疫苗安全，没有太大的副作用，与最新的化疗相比可更好地延长患者的生命。
化疗是治疗癌症的常用方法，它的原理是利用化学药物毒杀癌细胞，但药物也会“误伤”一些健康细胞，副作用较大。而本次试验的疫苗是促进人体自身免疫系统攻击癌细胞，副作用较小。
进行研究的汉斯—格奥尔格·赖门泽教授说，这项研究成果在癌症免疫疗法方面具有重要意义，因为它证明了利用人体自身免疫系统治疗癌症的可行性，而这是一个可用于所有癌症治疗的原则。他和同事还正在研究用类似方法来治疗肝癌和卵巢癌等其他癌症。
Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival
Steffen Walter, Toni Weinschenk, Arnulf Stenzl, Romuald Zdrojowy, Anna Pluzanska, Cezary Szczylik, Michael Staehler, Wolfram Brugger, Pierre-Yves Dietrich, Regina Mendrzyk, Norbert Hilf, Oliver Schoor, Jens Fritsche, Andrea Mahr, Dominik Maurer, Verona Vass, Claudia Trautwein, Peter Lewandrowski, Christian Flohr, Heike Pohla, Janusz J Stanczak, Vincenzo Bronte, Susanna Mandruzzato, Tilo Biedermann, Graham Pawelec et al.
Nature Medicine (2012) doi:10.1038/nm.2883
Received 28 February 2012 Accepted 20 June 2012 Published online 29 July 2012
IMA901 is the first therapeutic vaccine for renal cell cancer (RCC) consisting of multiple tumor-associated peptides (TUMAPs) confirmed to be naturally presented in human cancer tissue. We treated a total of 96 human leukocyte antigen A (HLA-A)*02+ subjects with advanced RCC with IMA901 in two consecutive studies. In the phase 1 study, the T cell responses of the patients to multiple TUMAPs were associated with better disease control and lower numbers of prevaccine forkhead box P3 (FOXP3)+ regulatory T (Treg) cells. The randomized phase 2 trial showed that a single dose of cyclophosphamide reduced the number of Treg cells and confirmed that immune responses to multiple TUMAPs were associated with longer overall survival. Furthermore, among six predefined populations of myeloid-derived suppressor cells, two were prognostic for overall survival, and among over 300 serum biomarkers, we identified apolipoprotein A-I (APOA1) and chemokine (C-C motif) ligand 17 (CCL17) as being predictive for both immune response to IMA901 and overall survival. A randomized phase 3 study to determine the clinical benefit of treatment with IMA901 is ongoing. Rojjer发表于 2012-8-1 16:29 |
感谢楼主分享！
查了一些资料，IMA901可以说是一种表位疫苗，基于tumor-associated antigen上的10个表位
（9个 HLA-class I- 和1 个HLA class II-binding peptides）设计而成，并且辅以了GM-CSF细胞因子佐剂，以诱导强烈的特异性CTL反应为目标。
目前，基于T细胞应答的疫苗设计还比较薄弱，个人觉得主要还是一个免疫指标评价以及免疫反应与保护（或治疗）效果的关系问题，IMA901的临床研究中相关免疫评价指标我想也会为其他同类疫苗的免疫评价提供较强的参考作用。
页:
[1]